Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Recombinant DNA01:09

Recombinant DNA

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monoclonal Antibodies Accessing the Cytosol of Living Cells and Binding to Polo-Like Kinase 1 Interdomain Linker Affect Mitotic Behavior.

Chembiochem : a European journal of chemical biology·2026
Same author

International multicentre evaluation of a new anti-idiotypic anti-daratumumab for resolving pre-transfusion interferences.

Vox sanguinis·2026
Same author

A Modular Supramolecular Peptide Platform Reveals Atomic-Number-Dependent Mechanisms Driving Radioenhancement.

ACS nano·2025
Same author

Pioneer: a synthetic human antibody phage display library for rapid therapeutic lead generation.

mAbs·2025
Same author

20 Years of Providing Custom Non-Animal-Derived Antibodies - A Review.

Alternatives to laboratory animals : ATLA·2025
Same author

Molecular mechanism of IKK catalytic dimer docking to NF-κB substrates.

Nature communications·2024

Related Experiment Video

Updated: Jul 3, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Recombinant monoclonal antibodies.

Mariel Donzeau1, Achim Knappik

  • 1Department of Research, MorphoSys AG, Martinsried, Germany.

Methods in Molecular Biology (Clifton, N.J.)
|July 9, 2008
PubMed
Summary
This summary is machine-generated.

Recombinant antibody technology uses genetic engineering to study and improve antibodies. This review covers producing engineered antibodies and performing immunoassays, highlighting their use in therapy and diagnostics.

More Related Videos

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Experiment Videos

Last Updated: Jul 3, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Area of Science:

  • Biotechnology
  • Immunology
  • Genetic Engineering

Background:

  • Recombinant antibody technology allows genetic engineering for antibody study and enhancement.
  • Functional expression of antibody fragments in Escherichia coli is key for antibody library generation.
  • In vitro-generated antibodies offer advantages over traditional monoclonal antibodies.

Purpose of the Study:

  • To review the production and engineering of recombinant antibodies.
  • To explain the performance of typical immunoassays using these antibodies.
  • To highlight the increasing use of recombinant antibodies in immunological assays.

Main Methods:

  • Genetic engineering techniques for antibody modification.
  • Functional expression of antibody fragments in Escherichia coli.
  • Antibody library generation and selection for therapeutic antibody production.

Main Results:

  • Recombinant antibodies can be engineered for improved properties.
  • Escherichia coli expression facilitates antibody library creation.
  • In vitro antibodies are increasingly adopted for immunological assays.

Conclusions:

  • Recombinant antibody technology is a rapidly advancing field.
  • Engineered antibodies produced via genetic engineering are valuable for research and therapy.
  • Recombinant antibodies are becoming standard in immunological assays due to their advantages.